Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.

Elizabeth A GarciaMary M K FooteTristan D McPhersonMaura K LashAmma N BosompemAlyssa BouscarenJustin ChanMadeline A DiLorenzoDennis FeihelRandal C FowlerVani GandhiElizabeth R Jenny-AvitalErik J KoppingDana MazoJacob McLeanOfole MgbakoMark N SayeghRaphael N ShawMichelle SuJeanne Sullivan MeissnerJade C WangWendy WenJohn C WintersCosmina B ZeanaJason E ZuckerMarcia Wong

Published in: Open forum infectious diseases (2024)

Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.

Keyphrases

human immunodeficiency virus
antiretroviral therapy
hepatitis c virus
hiv infected
hiv positive
hiv aids
early onset
induced apoptosis
hiv testing
drug induced
type diabetes
cardiovascular disease
cardiovascular events
cell cycle arrest
risk factors
oxidative stress
south africa
endoplasmic reticulum stress